PURASORB PLG 8531 Medical Device Lactide-Glycolide Copolymer is a purified, tin-catalyzed random copolymer of L-lactide and glycolide with a lactide-rich 85:15 monomer ratio. The grade designation encodes a nominal inherent viscosity of 3.1 dL/g, measured as a 0.1 g/dL solution in chloroform at 25°C; this places the material between PURASORB PLG 8523 and PURASORB PLG 8560 within the same copolymer chemistry. The product is supplied as white-to-off-white granules for melt-based conversion into absorbable medical-device components. It functions as an engineering resin for injection moulding, compression moulding, filament extrusion, and rod or profile extrusion where an intermediate molecular weight and lactide-rich hydrolysis profile are required. The polymer is not a finished device material: biological safety, mechanical performance, and absorption time are established on the final article after processing, sterilization, and packaging under ISO 10993-1:2018. The 85:15 composition suppresses crystallinity relative to poly(L-lactide) homopolymer and slows in vitro degradation relative to 50:50 PLGA grades of comparable inherent viscosity.

What Dilute-Solution and Thermal Data Are Used for Incoming Inspection?

For lot acceptance and incoming inspection, the most discriminating variables are dilute-solution viscosity, residual monomer, water content, tin content, and glass transition. Inherent viscosity is not a direct molecular weight measurement, but it tracks weight-average molecular weight through the Mark–Houwink relationship; a reduction in inherent viscosity below 2.9 dL/g indicates chain scission during storage, drying, or melt processing. The values in Table 1 represent the typical release envelope for PURASORB PLG 8531 and should be confirmed against the certificate of analysis for each lot.

Residual Moisture Below 250 ppm Is the Primary Processing Boundary

PLG 8531 is a hydrolytically unstable polyester in the melt. Trace water attacks the ester linkage during plastication, reducing molecular weight before the polymer enters the mould or die. Pre-drying in a vacuum oven at 40–50°C under a chamber pressure below 50 mbar for 4–8 h is standard for batch preparation. Continuous feeding is supported by a desiccant-bed hopper dryer with a supply-air dew point of −40°C. The target residual moisture before melt processing is below 250 ppm; moisture above this threshold can produce a measurable drop in inherent viscosity of 0.2–0.5 dL/g after a single pass through a L/D 32:1 twin-screw extruder, although published data for this exact screw configuration is limited. Drying validation is performed by Karl Fischer titration on granule samples taken at the feed throat.

Melt processing is constrained by a second pathway: thermal chain scission and monomer regeneration through intramolecular transesterification. Barrel settings from feed to nozzle are typically held between 160°C and 190°C, with nozzle melt temperature not exceeding 190°C. Residence time above 200°C should be limited to 5 min or less because lactide-rich PLGA of this viscosity range undergoes measurable random chain scission at elevated temperature. Injection moulding is performed with a general-purpose screw having a compression ratio of 2.5:1–3:1 and a back pressure below 10 MPa to limit shear heating. Capillary rheometry under ISO 11443 at 180°C is used to establish lot-to-lot melt viscosity; lactide-rich PLGA of this molecular weight range is strongly pseudoplastic, with a power-law index below 1 across shear rates from 100 s⁻¹ to 5000 s⁻¹. Hot-runner valve-gate systems reduce stagnant melt zones where lactide-rich degradation products can accumulate. Cavity pressures are generally maintained below 80 MPa, and ejection temperatures near 45°C reduce distortion because the material is above its glass transition but below the Vicat softening range.

Following melt conversion, the device enters a hydrolytically active service environment. PLG 8531 undergoes bulk erosion rather than surface erosion. Water uptake into the amorphous matrix precedes random ester hydrolysis, and the hydrolysis rate is accelerated by carboxylate end groups and acidic degradation products. In thick sections above 2 mm, internal pH can decrease as degradation products accumulate, producing a heterogeneous molecular weight profile across the cross-section. Under ISO 13781:2017 or ASTM F1635-16 in phosphate-buffered saline at 37°C, molecular weight decreases continuously during the early phase, while mass loss begins after a lag period. The 85:15 lactide-rich composition slows this process relative to 50:50 PLGA of similar inherent viscosity. Devices made from PLG 8531 are therefore intended for applications requiring longer strength retention than 50:50 grades, such as fracture fixation pins, suture anchors, and other absorbable osteosynthesis components. Mechanical performance should be verified on finished devices under ISO 527-2 or ISO 178; tensile modulus and strength depend strongly on orientation, moisture uptake, weld lines, and thermal history, and published data for this specific configuration is limited.

Comparing PLG 8523, PLG 8531, and PLG 8560

The principal difference within the 85:15 PLG series is inherent viscosity, which controls melt viscosity, processability, and load-bearing capability. PLG 8523 has a lower molecular weight and is selected when reduced melt viscosity is required for thin-wall injection moulding. PLG 8531 provides an intermediate molecular weight and is used when a balance between mechanical integrity and processability is required. PLG 8560 has a higher molecular weight and is more difficult to injection mould because of elevated torque and melt pressure; it is more often reserved for rod or profile extrusion and high-strength fiber drawing. Table 2 summarizes the series comparison.

Outside the PLG series, PLG 8531 differs from 50:50 PLGA copolymers primarily in degradation rate. The higher lactide content reduces water uptake and ester-bond accessibility. Under ISO 13781:2017 or ASTM F1635-16, an 85:15 PLGA of comparable inherent viscosity loses molecular weight more slowly than a 50:50 PLGA. Compared with poly(L-lactide) homopolymer, PLG 8531 has a lower glass transition temperature, lacks a semi-crystalline melting transition in its unprocessed state, and degrades more rapidly because the glycolide units interrupt stereoregularity and increase chain flexibility.

When Ethylene Oxide Sterilization Is Required Rather Than Gamma Irradiation

Selection of terminal sterilization interacts directly with PLG 8531. High-energy gamma irradiation at 25 kGy produces free radicals and chain scission in aliphatic polyesters; a single dose of 25 kGy can reduce molecular weight substantially, which would accelerate subsequent in vitro mass loss under ASTM F1635-16. Ethylene oxide sterilization is generally specified for implantable devices made from PLG 8531, with cycle temperatures below 40°C and relative humidity below 60% to limit autocatalytic hydrolysis. Electron beam sterilization may be considered only if dose mapping demonstrates that the maximum absorbed dose remains below 10 kGy; published data for this specific configuration is limited, and device-specific validation under ISO 11137-1 is required. Residual ethylene oxide limits after sterilization should be verified according to ISO 10993-7:2008.

A second boundary condition is chemical incompatibility. PLG 8531 should not be compounded with primary or secondary amine-based additives because aminolysis cleaves ester linkages. Strongly alkaline fillers and aqueous alkaline media accelerate hydrolysis and should be avoided. Solvent-based coating or spinning of this grade is performed in chlorinated solvents such as chloroform or dichloromethane; ketone or alcohol solutions may produce molecular weight loss if held for extended periods. The polymer should be stored in sealed foil bags at −20°C and low relative humidity. A cold bag should be allowed to reach room temperature before opening to prevent condensation on granule surfaces; surface moisture raises the water content of the feed and reduces the effective drying capacity of the hopper dryer.

Regulatory Dossier Elements for Medical-Grade Poly(L-lactide-co-glycolide) 85:15

Suppliers of PURASORB PLG 8531 typically provide a certificate of analysis, statements of manufacturing compliance to ISO 13485:2016, and supporting data for biological evaluation according to ISO 10993-1:2018. The biological evaluation may include cytotoxicity, sensitization, irritation, acute systemic toxicity, subacute or subchronic toxicity, and implantation studies, depending on device contact duration. The residual tin level is controlled because stannous octoate is a catalyst for transesterification and can affect degradation kinetics. Decomposition products at elevated temperatures include lactide, glycolide, carbon dioxide, and water. The device manufacturer retains responsibility for process validation under 21 CFR Part 820, for verifying final device biocompatibility under ISO 10993-5:2009 and ISO 10993-10:2010, and for generating application-specific degradation data under ISO 13781:2017 or ASTM F1635-16. Because this polymer is a raw material, lot-to-lot variation in inherent viscosity, residual monomer, and water content must be controlled within the incoming inspection plan and correlated with the melt-processing history of each device batch.